Ono Pharma Files Application in Japan for Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors Ono Pharmaceutical, headquartered in Osaka, Japan, under the leadership of President Toichi Takino, has announced the submission of a regulatory application in Japan for the…
WuXi Biologics Announces Record-Breaking Financial Performance for Fiscal Year 2025 WuXi Biologics has reported a year of strong financial performance and operational expansion for the fiscal year ending December 31, 2025, underscoring its growing influence as a leading global contract…
AbbVie Becomes Official Pharmaceutical Partner of Major League Baseball AbbVie has unveiled a landmark multi-year partnership with Major League Baseball (MLB), officially naming the company as the league’s “Official Pharmaceutical Partner” beginning with the 2026 season. This collaboration represents a…
Bristol Myers Squibb Strengthens Position in Obstructive Hypertrophic Cardiomyopathy with New Camzyos (mavacamten) Data Presented at ACC 2026 Bristol Myers Squibb has unveiled an extensive body of new clinical and real-world evidence supporting the continued evolution of Camzyos (mavacamten) as…
KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global Angioedema Leadership Conference, highlighting its continued commitment to advancing treatment…
Bristol Myers Squibb Redefines First-Line Treatment Landscape in Classical Hodgkin Lymphoma with Expanded U.S. and EU Approvals for Opdivo® (nivolumab) Bristol Myers Squibb today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S.…
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of its Annual General Meeting (AGM) held on March 19, 2026.…
TALZENNA in Combination with XTANDI Shows Marked Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Prostate Cancer Pfizer Inc. has announced compelling topline results from its Phase 3 TALAPRO-3 clinical trial, marking a potentially significant advancement in the treatment…
Celltrion Launches AVTOZMA® (tocilizumab-anoh) Subcutaneous Formulation in the U.S. Market Celltrion has announced a significant milestone in its ongoing efforts to expand access to biologic therapies in the United States, confirming that its biosimilar product AVTOZMA® (tocilizumab-anoh) is now commercially…
Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or…
ICON plc announces revised timeline for Q4 and full-year 2025 earnings as investigation into accounting practices continues. ICON plc, today announced that it intends to release its fourth quarter and full year 2025 earnings results on or prior to April 30,…
FDA Expands Approval of GSK’s RSV Vaccine Arexvy to Include At-Risk Adults Aged 18–49 GSK plc today announced that the US Food and Drug Administration (FDA) has expanded the approved age indication of Arexvy (Respiratory Syncytial Virus vaccine, [adjuvanted]) to…